Aflibercept 8 mg achieved meaningful improvement in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) across baseline quartiles in eyes with diabetic macular edema (DME), according to a posthoc analysis of the phase 2/3 PHOTON trial.
Presented at ARVO 2024, eyes with the thickest baseline CRT experienced numerically less fluid reaccumulation at 8 weeks after the last initial monthly dose of aflibercept 8 mg versus 2 mg aflibercept, indicating its durability.
“What that tells me as a treating retina specialist is that folks with more swollen retinas at baseline have more circulating VEGF that needs to be suppressed,” Deepak Sambhara, MD told HCPLive. “That also reiterates the importance of having a higher-dosed VEGF agent on the market that can contribute to that initial VEGF suppression, particularly in the more difficult-to-treat DME patient population.”
Highlights
0:08 Impact of baseline CRT on aflibercept 8 mg outcomes in DME
6:05 Importance of reducing treatment burden, extending intervals in DME
7:53 Recent advancements in ophthalmology, expectations for 2024
Link to full article: www.hcplive.com/view/deepak-s...
More ARVO coverage: www.hcplive.com/conference/arvo
#retina #ophthalmology #conference